Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 dose-escalation and expansion study of XB002 alone and in combination in advanced solid tumors
NL-OMON60457Phase 1Completed
- Sponsor
- Exelixis, Inc.
- Start
- Nov 2023
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of XB002 in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC) and 2 more (3 arms), sponsored by Exelixis, Inc. Primary endpoint: Safety. Started Nov 2023; status: completed.
02
Drugs
XB002
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)head and neck squamous cell carcinoma (HNSCC)Esophageal Squamous Cell Carcinoma (ESCC)epithelial ovarian cancer (EOC)
Beyond the preview
Go deeper on NL-OMON60457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60457.